Megan Baumgart, MD
Medical Oncology · Rochester, NYNPI 1881896157
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,037 of the $5,893 with a category attached, or 85.5%. E.r. Squibb & Sons, L.L.C. accounts for 71.6% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $4,186 and has fallen 99.5% since, to $21 in 2023. That places this record below the midpoint for medical oncology clinicians in NY, where the typical reported total is $4,912.
Across 11 payments — averaging $535.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$4K
- Beigene, Ltd.$2K
- Mirati Therapeutics, Inc.$21
Across 34 payments — averaging $15,443 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$384K
- Pfizer$124K
- Iovance Biotherapeutics, Inc.$10K
- Astrazeneca UK Limited$7K
- AstraZeneca$143
What the payments were for
- Consulting fees$5,03785%
- Travel & lodging$63011%
- Food & beverage$1703%
- Education$571%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 9 | $4,222 |
| Beigene, Ltd. | 1 | $1,650 |
| Mirati Therapeutics, Inc. | 1 | $21 |
How this compares
$5,893 in reported general payments places this provider in the 50th percentile of 498 medical oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prochlorperazine Maleate | 63 | $826 |
| Dexamethasone | 19 | $278 |
| Ondansetron Hcl | 51 | $199 |
| Levothyroxine Sodium | 32 | $149 |
| Gabapentin | 19 | $107 |
| Oxycodone Hcl | 21 | $100 |
| Prednisone | 13 | $85 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Rochester
- Susan DentRochester$139K
- Craig ThompsonNew York$4.8M
- Andrew SeidmanNew York$1.3M
- Maria TheodoulouAlbany$1.1M
- Joshua RichterNew York$971K
- Edward GelmannNew York$944K
- Anthony MatoIthaca$909K
- Ehsan MalekBuffalo$826K
- Ghassan Abou-AlfaNew York$825K
- Miguel PeralesNew York$769K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.